FGFR as potential target in the treatment of squamous non small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Therapeutic options for squamous cell lung cancer (SCC) are limited due to a lack of identified druggable targets.
• Aberrant signaling of fibroblast growth factors (FGFs) and their receptors (FGFRs) is implicated in various cancers, notably squamous non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To review current knowledge on FGFR alterations in NSCLC.
• To summarize the development of FGFR inhibitors for squamous NSCLC.

Main Methods:

• Literature review of studies on FGFR alterations and inhibitors in NSCLC.
• Analysis of mechanisms driving aberrant FGFR signaling, including gene amplifications, mutations, and translocations.

Main Results:

• Aberrant FGFR signaling is a frequent mechanism in squamous NSCLC.
• FGFR alterations can serve as a negative prognostic factor but predict sensitivity to FGFR inhibitors.
• Various FGFR inhibitors, including monoclonal antibodies, ligand traps, and tyrosine kinase inhibitors, are under clinical investigation.

Conclusions:

• FGFR alterations represent a potential therapeutic target in squamous NSCLC.
• Targeted therapies inhibiting FGFR signaling show promise for treating this subset of lung cancer.
• Further research and clinical evaluation of FGFR inhibitors are warranted for squamous NSCLC patients.